Connect patients with treatments
What we commit to
We will continue to work closely with healthcare providers, patient organisations and regulatory authorities to make our therapies available to those who can benefit from them, connecting efforts to break down geographic, economic and social barriers.
We commit to streamlining access to treatments, including exploring and collaborating with healthcare providers to ensure timely and efficient delivery of therapies.
What we have done so far
At Sobi, we work with communities to increase patient access through the established healthcare system. In some countries, Sobi has managed access programmes for people living with life-threatening diseases with no other option available.1
Sobi has an established process for emergency orders within the EU and the US for life-saving medicines, which are also available during non-office hours 365 days a year for immediate service if needed to save a person’s life.1
Through long-standing partnerships with other companies, Sobi has successfully commercialised a generation of extended-half-life products for haemophilia in Europe, the Middle East and North Africa.2 These treatments provide improved efficacy and convenience for people with this rare bleeding disorder.
Sobi also supports people living with rare diseases and healthcare providers in navigating reimbursement processes in markets where access may be limited.3
Measurement
We will measure impact through:
- Number of products with managed access in place
- Number of new countries impacted
Involvement
The Sobi departments involved are:
- Value and Access
- Patient Engagement
- Commercial
- Medical
- Compliance
- Legal (depending on project)
References:
- Sobi. Annual and Sustainability Report 2022. Available at: https://www.sobi.com/sites/default/files/pr/202303312874-1.pdf.
- Nature. Leading the Way in Rare Disease. Available at: https://www.nature.com/articles/d43747-020-00680-6.
- Sobi. Expanded Access to Treatment. Available at: https://www.sobi.com/en/access-treatment.